Cost-effective analysis the value component of evidence-based medicine

Evidence-Based Eye Care

Volumn 1, Issue 1, 1999, Pages 54-57

  Brown, Melissa M ^a   Brown, Gary C ^a   Sharma, Sanjay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013291983     PISSN: 15258599     EISSN: 15364836     Source Type: Journal    
DOI: 10.1097/00132578-199910000-00027     Document Type: Article

References (17)

1. Branch Retinal Win Occlusion Study Group. Argon laser for m.uulai edema in branch vein occlusion. Am J Ophthalmol 1989,98:271-282.
2. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
3. Gold Mb, Siegel JE, Russell LB, Weinstein MC. Cost-Eßecttveness tn Health and Medicine. New York: Oxford University Press, 1996.
4. Brown MM, Broun GC Sharma S, Garrett S. Evidence-based medicine, utilities and quality of life CurrOpin Ophthalmol 1999;10:221-228.
5. Angell M. Patients’ preferences in randomized clinical trials. A Engl J Med 1984;310:1385-1387.
6. Kassirer JP. Incorporating patients' preferences into medical decisions N Engl J Med 1999:330: 1895-1896.
7. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14: an index of functional impairment in patients with cararact Arch Ophthalmol 1994;112: 630 -638.
8. Ware JE Jr., Sherbourne CD. THe MOS 36-item short-form health survey (SE-36). Med Care 1992. 30:473-483.
9. Redelmeier DA. Detskv AS. A clinician's guide to unlitv measurement. In: Bergus GR, C.anror SB. eds. Primary C are: Clones m Office Practice. Philadelphia. PA: WB Saunders, 1995:271- 280.
10. Sonnenberg EA, Beck JR. Markov models m medical decision making, a practical guide. Med Dec is Making 1993:13 322 -338.
11. Damodaran A Corporate Finance: Theory and Practice. New York. John Wiley & Sons, 1997:37 65
12. Brown GC, Brown MM, Sharma S, Tasman W, Broun H. Cost-effectiveness of treatment lor threshold retinopathy of prematurity. Pediatrcs (in press)
13. Laupatis A, Eernv D, Detskv AS, Tugvvell PX How attractive does a new technology have to be to w ar rant adoption and unification. Tentative guidelines lot using dum al and economic evaluations Can MvdAssmJ 1992:146:473- 481.
14. United States Department of Health and Human Services. Vital Statistics ofUnited States, 1999. Preprint of Volume 11, Mortality, Part A, Section 6, 1 Hansville. MD. U.S Department of Health and Human Services, DHHS data Publication No (PHS) 98 1104, 1998.
15. Brown GC Vision and quality of life, Trans Am Ophthalmol Soc (in press).
16. Davis JB. Medical Fees m the United States Satnmu-nle Charges for Mediane, Surgery, laboratory. Radiology and Allied Health Services. Los Angeles: Practice Management Information Corporation, 1999
17. Cardmale V, ed. 1999 Drug Topics Red Rook Montvale, N: Medical Economics Company. 1999: 418.